Impaired response or insufficient dosage?-Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 2, 2014, Pages 170-174

  Stamp, Lisa K ^a   Merriman, Tony R ^b   Barclay, Murray L ^c   Singh, Jasvinder A ^d,e   Roberts, Rebecca L ^b   Wright, Daniel F B ^b   Dalbeth, Nicola ^f  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Allopurinol; Drug resistance; Gout; Oxypurinol

Indexed keywords

ALLOPURINOL; FUROSEMIDE; OXIPURINOL; ANTIGOUT AGENT; BIOLOGICAL MARKER; URIC ACID;

CREATININE CLEARANCE; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GOUT; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY EXCRETION; BLOOD; DOSE RESPONSE; TREATMENT FAILURE;

ALLOPURINOL; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GOUT; GOUT SUPPRESSANTS; HUMANS; PATIENT COMPLIANCE; TREATMENT FAILURE; URIC ACID;

EID: 84927574979     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.05.007     Document Type: Review

References (31)

1. Winnard D., Wright C., Taylor W., Jackson G., Te Karu L., Gow P., et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 2012, 51:901-909.
2. Becker M., Schumacher H.R., Benjamin K., Gorevic P., Greenwald M., Fessel J., et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009, 36:1041-1048.
3. Dalbeth N., Collis J., Gregory K., Clark B., Robinson E., McQueen F. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 2007, 46:1804-1807.
4. Li-Yu J., Clayburne G., Sieck M., Beutler A., Rull M., Eisner E., et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?. J Rheumatol 2001, 28:577-580.
5. Khanna D., Fitzgerald J., Khanna P., Sangmee B., Singh M., Neogi T., et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res 2012, 64:1431-1446.
6. Becker M., Schumacher H.R., Wortmann R., MacDonald P., Eustace D., Palo W., et al. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N Engl J Med 2005, 353:2450-2461.
7. Stamp L., O'Donnell J., Zhang M., James J., Frampton C., Barclay M., et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Arthritis Rheum 2011, 63:412-421.
8. Zandman-Goddard G., Amital H., Shamrayevsky N., Raz R., Shalev V., Chodick G. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology 2013, 52:1126-1131.
9. Hande K., Noone R., Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
10. Dalbeth N., Kumar S., Stamp L.K., Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout. J Rheumatol 2006, 33:1646-1650.
11. Dalbeth N., House M., Horne A., Petrie K., McQueen F., Taylor W. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord 2012, 13:174.
12. Perez-Ruiz F., Alonso-Ruiz A., Calabozo M., Herrero-Beites A., Erauskin G., Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998, 57:545-549.
13. Stamp L., Barclay M., O'Donnell J., Zhang M., Drake J., Frampton C., et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharm Ther 2011, 90:392-398.
14. Wright D., Stamp L., Merriman T., Barclay M., Duffull S., Holford N. A population pharmacokinetic model for allopurinol and oxypurinol in patients with gout. Eur J Clin Pharmacol 2013, 69:1411-1421.
15. Graham S., Day R., Wong H., McLachlan A., Bergendal L., Miners J., et al. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 1996, 41:299-304.
16. Reiter S., Simmonds H.A., Zollner N., Braun S.L., Knedel M. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol. Clin Chim Acta 1990, 187:221-234.
17. Shibutani Y., Ueo T., Yamamoto T., Takahashi S., Moriwaki Y., Higashino K. A case of classical xanthinuria (type 1) with diabetes mellitus and Hashimoto's thyroiditis. Clin Chim Acta 1999, 285:183-189.
18. Schwarz G. Molybdenum cofactor biosynthesis and deficiency. Cell Mol Life Sci 2005, 63:2792-2810.
19. Smith M., Marinaki A., Arenas M., Shobowale-Bakre M., Lewis C., Ansari A., et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009, 30:375-384.
20. Hartmann T., Terao M., Garattini E., Teutloff C., Alfaro J., Jones J., et al. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos 2012, 40:856-864.
21. A map of human genome variation from population-scale sequencing. Nat Genet 2010, 467. The 1000 Genomes Project Consortium. 10.1038/nature09534.
22. Iwanaga T., Kobayashi D., Hirayama M., Maeda T., Tamai I. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005, 33:1791-1795.
23. Kottgen A., Albrecht E., Teumer A., Vitart V., Krumsiek J., Hundertmark C., et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013, 45:145-154.
24. Graham G., Kannangara D., Stocker S., Portek I., Pile K., Indraratna P., et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol 2013, 76:932-938.
25. Kudo M., Moteki T., Sasaki T., Konno Y., Ujiie S., Onose A., et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics 2008, 18:243-251.
26. So A., Thorens B. Uric acid transport and disease. J Clin Invest 2010, 120:1791-1799.
27. Merriman T., Dalbeth N. The genetic basis of gout. Joint Bone Spine 2011, 78:35-40.
28. Hagos Y., Stein D., Ugele B., Burckhardt G., Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007, 18:430-439.
29. McAdams-Demarco M., Maynard J., Baer A., Kao L., Kottgen A., Coresh J. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study. Ann Rheum Dis 2013, 72:701-706.
30. Pui K., Gow P., Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol 2013, 40:872-876.
31. Khanna P., Hagerty D., Mischler R., Morlock R. Adherence to EULAR recommendations for the treatment of gout. Ann Rheum Dis 2012, 71(Suppl. 3):448.